

node (LN) status. LN assessment by imaging methods has several known limitations including a high false negative rate. The present study aimed to compare the accuracy of LN staging by imaging and surgical staging in LACC patients, and to evaluate their impact on radiation field planning.

Methodology A retrospective monocentric study of patients with LACC (International Federation of Gynecology and Obstetrics (FIGO 2018) stage IIA -IVA), undergoing primary definitive platinum-based chemoradiation therapy. Patients were included if LN assessment was available by both methods: surgical (paraaortic/pelvic) and imaging [Thorax/Abdomen Computed Tomography (CT) and/or pelvic Magnetic Resonance Imaging (MRI)].

Result(s)* A total of 58 patients met the inclusion criteria (table 1), 97% (n=56) had a preoperative CT and 88% (n=51) an MRI evaluation. All patients underwent surgical LN staging: 100% paraaortic, and 86% (n=50) additional pelvic lymphadenectomy. Histologically proven LN metastases after surgical LN staging were found in 76% of patients (n=44), 31% (n=18) paraaortic and 76% (n=38) pelvic. As a result of the surgical LN staging, 36% (n=21) of the patients were upstaged (n=11 to FIGO IIIC1 and n=10 to FIGO IIIC2), and 17% (n=10) had treatment modification (extended paraaortic field radiation). LN staging using CT and MRI exhibited a low negative predictive value (29% and 38%, respectively), with a higher positive predictive value (69% and 81%, respectively).

Conclusion* In this cohort of LACC patients, paraaortic LN metastases were present in one third of the cases, while CT/MRI imaging underestimated metastatic LN involvement. We thus stress the value of surgical paraaortic LN staging in cases of negative LN imaging, which may lead to treatment modification in about one fifth of patients.

898

THE IMPACT OF MICROMETASTASES IN CERVICAL CANCER PATIENTS – A RETROSPECTIVE STUDY OF THE SCCAN (SURVEILLANCE IN CERVICAL CANCER) PROJECT

¹L Dostalek*, ¹M Borcinova, ²K Benesova, ³J Klat, ⁴H Falconer, ⁵SH Kim, ⁶LR Van Lonkhuijzen, ⁷A Lopez, ⁸D Isla Ortiz, ⁹F Landoni, ¹⁰J Kostun, ¹¹R Dos Reis, ¹²D Odetto, ¹³J Zapardiel, ²J Jarkovsky, ³V Javukova, ⁴S Salehi, ⁵NR Abu-Rustum, ³P Graf, ¹D Cibula.

¹Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Central and Eastern European Gynecologic Oncology Group, (CEEGOG), Prague, Czech Republic; ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; ³Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic; ⁴Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ⁵Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; ⁶Department of Gynecological Oncology, Amsterdam University Medical Center—Center for Gynecological Oncology Amsterdam, Amsterdam, the Netherlands; ⁷Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru; ⁸Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico; ⁹University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy; ¹⁰Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic; ¹¹Departamento de Ginecología Oncológica, Hospital de Amor – Barretos, Brazil; ¹²Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina; ¹³Gynecologic Oncology Unit, La Paz University Hospital – IdiPAZ, Madrid, Spain

10.1136/ijgc-2021-ESGO.74

Introduction/Background* The impact of lymph node (LN) micrometastases (MIC) in cervical cancer patients remains a controversial topic given their low incidence and good prognosis of patients managed by primary surgery.


We aim to evaluate the prognostic significance of MIC and isolated tumour cells (ITC) in a large cohort of patients from the SCCAN retrospective study (Surveillance in Cervical Cancer). SCCAN study analysed data from more than 4300 patients with early stage cervical cancer treated by primary surgery at 20 large tertiary institutions from Europe, North America, South America and Australia.

Methodology In this SCCAN sub-study, we included patients with early stage cervical cancer (T1a1 LVSI+ – T2b) treated between 2007 and 2016 with at least 1-year follow-up data availability, who underwent primary surgery including sentinel lymph node (SLN) biopsy and in whom SLNs were processed by pathological ultrastaging protocol.

Abstract 898 Table 1 Data summary (N = 969)

Characteristics	Description	
Tracer type	Radiocolloid	423 (43.7%)
	Dye	662 (68.3%)
	ICG	220 (22.7%)
No. of SLN detected	Mean ± SD	3.2 ± 2.2
Largest type of metastasis in LN including SLN	Negative	795 (82.0%)
	ITC	31 (3.2%)
	MIC	59 (6.1%)
Surgical approach	MAC	84 (8.7%)
	Open	575 (59.3%)
	Robotic	195 (20.1%)
Tumour histotype	Laparoscopic	199 (21.5%)
	Squamous	605 (62.4%)
	Adenocarcinoma	287 (29.6%)
	Adenosquamous	50 (5.2%)
	Neuroendocrine	18 (1.9%)
Grade	Other	9 (0.9%)
	1	149 (15.4%)
	2	406 (41.9%)
	3	246 (25.4%)
	N/A	168 (17.3%)
	LVSI	No
	Yes	351 (36.2%)
Maximal pathologic tumour diameter [mm]	N/A	302 (31.2%)
	Mean ± SD	20.6 ± 13.7
	Median (IQR)	19 (10; 30)
	< 0.5 cm	73 (7.5%)
	0.5–1.99 cm	424 (43.8%)
Adjuvant therapy if yes:	2–3.99 cm	376 (38.8%)
	≥ 4 cm	96 (9.9%)
	radiotherapy	312 (32.2%)
	chemoradiotherapy	153 (49.0%)
	chemotherapy	136 (43.6%)
Recurrence	chemotherapy + radiotherapy	18 (5.8%)
	chemotherapy + chemotherapy	5 (1.6%)
		117 (12.1%)

Disease-free survival: All patients by largest type of metastasis in LN (N = 969)



Number at risk (cumulative number of events)

	0	1	2	3	4	5
Negative	795 (0)	763 (31)	721 (49)	501 (62)	364 (66)	223 (69)
ITC	31 (0)	29 (2)	27 (3)	19 (5)	15 (5)	12 (5)
MIC	59 (0)	55 (4)	51 (8)	38 (12)	28 (15)	23 (15)
MAC	84 (0)	78 (6)	71 (12)	54 (16)	45 (18)	29 (19)

Abstract 898 Figure 1

Abstract 898 Table 2 Univariate analysis of factors associated with disease-free survival (N = 969)

Predictor	Category	n	HR (95% CI)	p-value
Surgical approach	Open	575	Ref.	
	Robotic	195	1.21 (0.74; 1.97)	0.439
	Laparoscopic	141	1.51 (0.93; 2.45)	0.097
	Combined	58	1.06 (0.48; 2.31)	0.888
Tumour diameter	< 0.5 cm	73	Ref.	
	0.5–1.99 cm	424	1.67 (0.51; 5.47)	0.399
	2–3.99 cm	376	3.98 (1.25; 12.69)	0.019
	≥ 4 cm	96	6.35 (1.91; 21.13)	0.003
LVSI	No	316	Ref.	
	Yes	351	2.31 (1.47; 3.63)	< 0.001
Tumour histotype	Squamous	605	Ref.	
	Adenocarc.	287	1.13 (0.75; 1.71)	0.554
	Adenosquamous	50	1.38 (0.66; 2.89)	0.385
	Other	27	3.03 (1.45; 6.31)	0.003
Grade	1	149	Ref.	
	2	406	2.08 (1.02; 4.22)	0.044
	3	246	3.35 (1.64; 6.85)	< 0.001
Largest type of metastasis in LN	Negative	795	Ref.	
	ITC	31	1.67 (0.68; 4.14)	0.264
	MIC	59	2.55 (1.47; 4.43)	< 0.001
	MAC	84	2.36 (1.44; 3.87)	< 0.001
Largest type of metastasis in LN	Negative	795	Ref.	
	ITC	31	1.67 (0.68; 4.14)	0.264
	MIC+MAC	143	2.44 (1.63; 3.64)	< 0.001

Result(s)* Out of 969 included patients with at least 1 SLN detected, 174 (18%) had positive LN (table 1). Maximal tumour diameter >2cm, positive LVSI, grade ≥ 2, uncommon histological type (neuroendocrine, sarcoma, etc.) and macro-metastasis (MAC) or MIC in LN were factors associated with significantly decreased five-years disease free survival (DFS) (table 2). MAC, MIC or ITC was the largest LN metastasis in 84 (9%), 59 (6%) and 31 (3%) cases respectively. Adjuvant (chemo)radiation was administered in 89%, 85% and 58% of patients with MAC, MIC and ITC. DFS reached 75%, 73% and 83% in patients with MAC, MIC and ITC compared with 90% in the N0 patients. Patients with MAC and MIC had significantly decreased DFS than those with N0 disease (HR=2.36 and 2.55).

Conclusion* Early-stage cervical cancer patients with MIC in pelvic LN have significantly decreased DFS. Their management should follow the same principles as in patients with MAC.

917

PHASE 1B TRIAL OF FIRST-LINE BINTRAFUSP ALFA, A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-β AND PD-L1, PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN CERVICAL CANCER

¹A Oaknin*, ²M Gil-Martin, ³E Diver, ⁴G Jehl, ⁴SA Gleicher, ⁵S Chaudhary, ⁵L Ojalvo, ⁶K Hasegawa. ¹Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ²ICO Hospital Duran i Reynals, Barcelona, Spain; ³Stanford Cancer Institute, Stanford, CA, USA; ⁴Merck KGaA, Darmstadt, Germany; ⁵EMD Serono Research and Development Institute, Inc., Billerica, MA, USA; ⁶Saitama Medical University International Medical Center, Hidaki-shi, Saitama-ken, Japan

10.1136/ijgc-2021-ESGO.75